Specific Gene Mutations predict Success of glioblastoma immunotherapy

Testing for specific gene mutations may help to predict the patients with glioblastoma who will respond to immunotherapy, according to new research. The findings, published in the journal Nature Medicine also suggest a therapeutic target that could lead to improved immunotherapy in these patients.

Glioblastoma, the most common type of brain cancer, still lacks effective treatment. A type of immunotherapy called immune checkpoint inhibitors — which block the interaction between the PD-L1 protein in cancer cells and PD-1 in immune cells, boosting the anti-cancer response — has had success in diverse tumour types, such as Hodgkin’s lymphoma. In contrast, a Phase 3 trial of PD-1 blockers (NCT02017717) showed effectiveness in only 8% of patients with glioblastoma.

Responses to anti-PD1 therapies are linked to the infiltration of immune cells in the tumour microenvironment in various cancer types. The more cells within a tumour and the area surrounding it, the more likely a patient will respond to these treatments. However, glioblastoma is characterized by higher immunosuppression and a low rate of mutations, both of which are associated with poor responses to immune checkpoint inhibitors.


Other news

Upcoming Events

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Focus 2019

SEC Glasgow
1-3 May 2019

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Feb 2019

Early disease detection: a collaborative approach

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.